That’s binx io.
The world’s first FDA-cleared, molecular point-of-care test providing central lab quality results in about 30 minutes for chlamydia and gonorrhea in women and men.
Want to know more?
Welcome to the future of sexually transmitted infection (STI) testing. binx io is the first ever, FDA-cleared, molecular point-of-care platform that enables clinicians to test and treat women and men for the most common STIs, chlamydia and gonorrhea, in a single office visit.
binx io is a new paradigm designed to enable improved health outcomes by:
- Increasing treatment compliance
- Limiting the spread of infections
- Minimizing the risk of untreated conditions
- Taking the guesswork out of patient care and ensuring the the right antibiotic is used
Lab-quality test results in about 30 minutes
Test and treat patients in a single visit
Over the past five years, rates of sexually transmitted infections (STIs) have hit an all-time high. Over 1.8 million cases of chlamydia and 583,405 cases of gonorrhea were reported in 2018—and many more STIs go undiagnosed each year—leading to serious health problems including infertility.⁽¹⁾
Testing for sexually transmitted infections can take anywhere from days to weeks. Though all of these infections are treatable, and most are curable, up to 40% of positive patients in the U.S. don’t complete treatment once they leave their doctor’s office.⁽²⁾ The World Health Organization (WHO) has long recognized the need for a point-of-care diagnostic that is small, easy-to-use and provides prompt and accurate results.
The first-of-its-kind, binx io has the potential to transform STI care by offering a more efficient care pathway for both patients and providers.
Simply collect sample, load cartridge, and press ‘start’
View results in about 30 minutes
Get high-quality performance in a compact device
binx io is a small, desktop instrument that processes a single-use, assay-specific cartridge with no sample preparation necessary. binx io is fully automated and easy to use. Simply load the cartridge into the device and in about 30 minutes, the io provides easy-to-understand results that does not require interpretation. Operators at the point of care can run the test on-site at your clinic and there’s no calibration or preventive maintenance required.
How binx io works
binx io combines ultra-rapid, polymerase chain reaction (PCR) amplification with binx health’s proprietary and highly sensitive electrochemical detection technology. This combination allows the binx io to return accurate results that meet laboratory standards—in about 30 minutes. With billable testing administered under one roof, the io system generates valuable revenue for clinics.
The binx io has been cleared by the FDA for use in point-of-care and clinical laboratory settings for the rapid and accurate detection of chlamydia and gonorrhea in vaginal swab and first catch urine samples collected by either a clinician or patient.
Reserve your binx io now
Be the first to use a binx io in your clinic. You can sign up to reserve your spot now. Reservations are non-binding.
Learn more about binx
binx’ transformative in-clinic and at-home solutions are designed to better care and reach new populations. We’re dedicated to making STI care more accessible and convenient.
Want to know more?
*io®, the io Instrument®, and the io Cartridge® (together the “io Diagnostic System®”) are registered trademarks of binx health limited. Copyright © 2020 binx health, inc. The binx health io CT/NG Assay, when tested using the binx health io Instrument, is a fully automated, rapid, qualitative test intended for use in point-of-care or clinical laboratory settings for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae DNA by polymerase chain reaction. The binx health io CT/NG Assay is intended for use with female vaginal swab specimens, collected either by a clinician or self-collected by a patient in a clinical setting, or male urine specimens, as an aid in the diagnosis of symptomatic or asymptomatic Chlamydia trachomatis and/or Neisseria gonorrhoeae infection. For a symptomatic male patient with a chlamydia negative test result, further testing with a laboratory-based molecular test is recommended.
¹ The U.S. Centers for Disease Control and Prevention (2018). 2018 SEXUALLY TRANSMITTED DISEASES SURVEILLANCE REPORT. Updated August 27, 2019. https://www.cdc.gov/std/stats18/default.htm.
²,³ Huang W, Gaydos CA et al (2012). Comparative effectiveness of a rapid point-of-care test for detection of Chlamydia trachomatis among women in a clinical setting. STI. 88. Published first online 14 Sept 2012. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3671871/